Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?
Abstract
:1. Introduction
2. Case Reports
2.1. Case 1
2.2. Case 2
2.3. Case 3
3. Discussion
4. Methods
4.1. Patients
4.2. Cytokines’ Evaluation
4.3. MRI and Histological Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Niederwieser, D.; Baldomero, H.; Szer, J.; Gratwohl, M.; Aljurf, M.; Atsuta, Y.; Bouzas, L.F.; Confer, D.; Greinix, H.; Horowitz, H.; et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016, 51, 778–785. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ip, W.W.; Qasim, W. Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation. Adv. Hematol. 2013, 2013, 176418. [Google Scholar] [CrossRef] [Green Version]
- Feuchtinger, T.; Matthes-Martin, S.; Richard, C.; Lion, T.; Fuhrer, M.; Hamprecht, K.; Handgretinger, R.; Peters, C.; Schuster, F.R.; Beck, R.; et al. Safe adoptive transfer of virus-specific T-cell immunity for the treat-ment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 2006, 134, 64–76. [Google Scholar] [CrossRef] [PubMed]
- Leen, A.M.; Tripic, T.; Rooney, C.M. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin. Biol. Ther. 2010, 10, 337–351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chan, S.T.; Logan, A.C. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplanta-tion: Why the quest for meaningful prophylaxis still matters. Blood Rev. 2017, 31, 173–183. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Zhang, X.; Feng, S. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2018, 24, 1341–1349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- George, D.; El-Mallawany, N.K.; Jin, Z.; Geyer, M.; Della-Latta, P.; Satwani, P.; Garvin, J.H.; Bradley, M.B.; Bhatia, M.; van de Ven, C.; et al. Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality. Br. J. Haematol. 2012, 156, 99–108. [Google Scholar] [CrossRef]
- Sutrave, G.; Gottlieb, D.J. Adoptive cell therapies for post transplant infections. Curr. Opin. Oncol. 2019, 31, 574–590. [Google Scholar] [CrossRef]
- Walls, T.; Shankar, A.G.; Shingadia, D. Adenovirus: An increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect. Dis. 2003, 3, 79–86. [Google Scholar] [CrossRef]
- Koeken, V.A.C.M.; Ganiem, A.R.; Dian, S.; Ruslami, R.; Chaidir, L.; Netea, M.G.; Kumar, V.; Alisjahbana, B.; van Crevel, R.; van Laarhoven, A. Cerebrospinal fluid IL-1β is elevated in tuberculous meningitis patients but not associated with mortality. Tuberculosis 2020, 126, 102019. [Google Scholar] [CrossRef]
- Šumanović-Glamuzina, D.; Čulo, F.; Čulo, M.I.; Konjevoda, P.; Jerković-Raguž, M. A comparison of blood and cerebrospinal fluid cytokines (IL-1β, IL-6, IL-18, TNF-α) in neonates with perinatal hypoxia. Bosn. J. Basic Med. Sci. 2017, 17, 203–210. [Google Scholar] [CrossRef] [Green Version]
- Krebs, V.L.; Okay, T.S.; Okay, Y.; Vaz, F.A. Tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 in the cerebrospinal fluid of newborn with meningitis. Arq. Neuropsiquiatr. 2005, 63, 7–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lindqvist, D.; Janelidze, S.; Hagell, P.; Erhardt, S.; Samuelsson, M.; Minthon, L.; Hansson, O.; Björkqvist, M.; Träskman-Bendz, L.; Brundin, L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 2009, 66, 287–292. [Google Scholar] [CrossRef] [PubMed]
- Liu, Q.; Gao, Y.; Zhang, B.; Sun, F.; Yang, Q.; Liu, Y.; Wu, J.; Chen, K.; Weng, X.; Zhang, W.; et al. Cytokine profiles in cerebrospinal fluid of patients with meningitis at a tertiary general hospital in China. J. Microbiol. Immunol. Infect. 2018, 53, 216–224. [Google Scholar] [CrossRef] [PubMed]
- Is, M.; Coskun, A.; Sanus, G.Z.; Tanriverdi, T.; Kafadar, A.M.; Hanimoglu, H.; Tanriover, N.; Gezen, F.; Uzan, M.J. High-sensitivity C-reactive protein levels in cerebrospinal fluid and serum in severe head injury: Relationship to tumor necrosis factor-alpha and interleukin-6. Clin. Neurosci. 2007, 14, 1163–1171. [Google Scholar] [CrossRef]
- Pinto Junior, V.L.; Rebelo, M.C.; Gomes, R.N.; Assis, E.F.; Castro-Faria-Neto, H.C.; Bóia, M.N. IL-6 and IL-8 in cerebrospinal fluid from patients with aseptic meningitis and bacterial meningitis: Their potential role as a marker for differential diagnosis. Braz. J. Infect. Dis. 2011, 15, 156–158. [Google Scholar] [CrossRef] [Green Version]
- Lee, K.Y.; Seol, J.H.; Yi, C.H.; Lee, W.H. Cerebrospinal fluid type I interferon and cytokine profiles in enteroviral meningitis according to the presence or absence of pleocytosis. Pediatr. Neonatol. 2021, 62, 305–311. [Google Scholar] [CrossRef]
- Nagashima, H.; Morio, Y.; Yamane, K.; Nanjo, Y.; Teshima, R. Tumor necrosis factor-alpha, interleukin-1beta, and interleu-kin-6 in the cerebrospinal fluid of patients with cervical myelopathy and lumbar radiculopathy. Eur. Spine J. 2009, 18, 1946–1950. [Google Scholar] [CrossRef] [Green Version]
- Schwieler, L.; Larsson, M.K.; Skogh, E.; Kegel, M.E.; Orhan, F.; Abdelmoaty, S.; Finn, A.; Bhat, M.; Samuelsson, M.; Lundberg, K.; et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—Significance for activation of the kynurenine pathway. J. Psychiatry Neurosci. 2015, 40, 126–133. [Google Scholar] [CrossRef] [Green Version]
- Stelmasiak, Z.; Kozioł-Montewka, M.; Dobosz, B.; Rejdak, K. IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients. Med. Sci. Monit. 2001, 7, 914–918. [Google Scholar]
- Alexander, G.M.; Van Rijn, M.A.; Van Hilten, J.J.; Perreault, M.J.; Schwartzman, R.J. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005, 116, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Pilotto, A.; Masciocchi, S.; Volonghi, I.; De Giuli, V.; Caprioli, F.; Mariotto, S.; Ferrari, S.; Bozzetti, S.; Imarisio, A.; Risi, B.; et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences from Cerebrospinal Fluid Analyses. Clin. Infect. Dis. 2021, 73, e3019–e3026. [Google Scholar] [CrossRef] [PubMed]
- Comoli, P.; Maccario, R.; Locatelli, F.; Valente, U.; Basso, S.; Garaventa, A.; Toma, P.; Botti, G.; Melioli, G.; Baldanti, F.; et al. Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells. Am. J. Transplant. 2005, 5, 1415–1422. [Google Scholar] [CrossRef] [PubMed]
- Garcia Borrega, J.; Gödel, P.; Rüger, M.A.; Onur, Ö.A.; Shimabukuro-Vornhagen, A.; Kochanek, M.; Böll, B. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere 2019, 3, e191. [Google Scholar] [CrossRef] [PubMed]
- Maneiro, J.R.; Salgado, E.; Gomez-Reino, J.J. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: Systematic review and meta-analysis. JAMA Intern. Med. 2013, 173, 1416–1428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pranzatelli, M.R. Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. Front. Immunol. 2018, 9, 557. [Google Scholar] [CrossRef] [PubMed]
- Gough, P.; Myles, I.A. Tumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects. Front. Immunol. 2020, 11, 585880. [Google Scholar] [CrossRef] [PubMed]
- Lucas, R.; Juillard, P.; DeCoster, E.; Redard, M.; Burger, D.; Donati, Y.; Giroud, C.; Monso-Hinard, C.; De Kesel, T.; Buurman, W.A.; et al. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur. J. Immunol. 1997, 27, 1719–1725. [Google Scholar] [CrossRef] [PubMed]
- Pagnini, C.; Cominelli, F. Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention. Int. J. Mol. Sci. 2021, 22, 10273. [Google Scholar] [CrossRef]
- Infliximab. Drugs and Lactation Database (LactMed) [Internet]; National Library of Medicine: Bethesda, MD, USA, 2006. [Google Scholar]
- Kolho, K.L. Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Front. Pediatr. 2021, 8, 623689. [Google Scholar] [CrossRef]
- Clark, I.A.; Vissel, B. Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogen-esis Infer New Therapeutic Approaches. J. Alzheimers Dis. 2021, 79, 931–948. [Google Scholar] [CrossRef]
- Torres-Acosta, N.; O’Keefe, H.; O’Keefe, E.L.; Isaacson, R.; Small, G. Therapeutic Potential of TNF-alpha Inhibition for Alz-heimer’s Disease Prevention. J. Alzheimers Dis. 2020, 78, 619–626. [Google Scholar] [CrossRef]
- Zahid, M.; Busmail, A.; Penumetcha, S.S.; Ahluwalia, S.; Irfan, R.; Khan, S.A.; Reddy, S.R.; Lopez, M.E.V.; Mohammed, L. Tumor Necrosis Factor Alpha Blockade and Multiple Sclerosis: Exploring New Avenues. Cureus 2021, 13, e18847. [Google Scholar] [CrossRef]
- Schmitz, M.L.; Weber, A.; Roxlau, T.; Gaestel, M.; Kracht, M. Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. Biochim. Biophys. Acta 2011, 1813, 2165–2175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nathan, C. Points of control in inflammation. Nature 2002, 420, 846–852. [Google Scholar] [CrossRef] [PubMed]
- Möller, B.; Villiger, P.M. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin. Immunopathol. 2006, 27, 391. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, F.R.; Musella, A.; De Vito, F.; Fresegna, D.; Bullitta, S.; Vanni, V.; Guadalupi, L.; Stampanoni Bassi, M.; Buttari, F.; Mandolesi, G.; et al. Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation. Neural Plast. 2018, 2018, 8430123. [Google Scholar] [CrossRef] [Green Version]
- Kaur, D.; Sharma, V.; Deshmukh, R. Activation of microglia and astrocytes: A roadway to neuroinflammation and Alzheimer’s disease. Inflammopharmacology 2019, 27, 663–677. [Google Scholar] [CrossRef]
- Dhapola, R.; Hota, S.S.; Sarma, P.; Bhattacharyya, A.; Medhi, B.; Reddy, D.H. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology 2021, 29, 1669–1681. [Google Scholar] [CrossRef]
- Maximova, N.; Schillani, G.; Simeone, R.; Maestro, A.; Zanon, D. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis. Adv. Ther. 2017, 34, 1184–1199. [Google Scholar] [CrossRef]
- ClinicalTrials.gov Identifier: NCT04423237. Available online: https://clinicaltrials.gov/ct2/show/NCT04423237 (accessed on 27 February 2022).
- Li, X.; Shao, M.; Zeng, X.; Qian, P.; Huang, H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal. Transduct. Target. Ther. 2021, 6, 367. [Google Scholar] [CrossRef]
Subjects | Cytokine | CSF Control Values (pg/mL) |
---|---|---|
Koeken, V.A.C.M. et al. [10] | IL-1β | 0.19 (mean) |
Šumanović-Glamuzina, D. et al. [11] | IL-1β | 0.05 (median) |
IL-6 | 7.00 (median) | |
TNF-α | 16.20 (median) | |
Krebs, V.L. et al. [12] | IL-1β | 0.0 (median) |
IL-6 | 5.1 (median) | |
TNF-α | 0.0 (median) | |
Lindqvist, D. et al. [13] | IL-1β | 0.07 (mean) |
IL-6 | 0.64 (mean) | |
TNF-α | 0.13 (mean) | |
Liu, Q. et al. [14] | IL-1β | 0.21 (median) |
IL-6 | 5.71 (median) | |
TNF-α | 3.32 (median) | |
Is, M. et al. [15] | IL-6 | 28.6 (mean) |
TNF-α | 14.4 (mean) | |
Pinto Junior, V.L. et al. [16] | IL-6 | 0.06 (median) |
Lee, K.Y. et al. [17] | IL-6 | 8.73 (median) |
Nagashima, H. et al. [18] | IL-1β | 0.35 (mean) |
IL-6 | 4.58; 5.14 (mean) | |
TNF-α | undetectable | |
Schwieler, L. et al. [19] | IL-6 | 1.50 (median) |
Stelmasiak, Z. et al. [20] | IL-6 | 0.87 (mean) |
Alexander, G.M. et al. [21] | IL-1β | 0.02 (mean) |
IL-6 | 1.32 (mean) | |
TNF-α | 0.11 (mean) | |
Pilotto, A. et al. [22] | IL-1β | 0.27 (median) |
IL-6 | 1.05 (median) | |
TNF-α | 0.17 (median) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marcuzzi, A.; Rimondi, E.; Melloni, E.; Zennaro, F.; Sonzogni, A.; Leo, S.; Maximova, N. Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity? Int. J. Mol. Sci. 2022, 23, 3553. https://doi.org/10.3390/ijms23073553
Marcuzzi A, Rimondi E, Melloni E, Zennaro F, Sonzogni A, Leo S, Maximova N. Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity? International Journal of Molecular Sciences. 2022; 23(7):3553. https://doi.org/10.3390/ijms23073553
Chicago/Turabian StyleMarcuzzi, Annalisa, Erika Rimondi, Elisabetta Melloni, Floriana Zennaro, Aurelio Sonzogni, Sara Leo, and Natalia Maximova. 2022. "Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?" International Journal of Molecular Sciences 23, no. 7: 3553. https://doi.org/10.3390/ijms23073553